Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial: Reply from the Authors

Neurology

Volumn 62, Issue 3, 2004, Pages 525-

  Mariotti, Caterina ^a   Taroni, Franco ^a   Di Donato, Stefano ^a  

^a NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85026171376     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. Wilson RB. Frataxin and frataxin deficiency in Friedreich’s ataxia. J Neurol 2003; 20: 103-105.
2. Rustin P, et al. Effect of idebenone on cardiomyopathy in Friedreich’s ataxia: a preliminary study. Lancet 1999; 354: 477-479.
3. Hausse AO, et al. Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia. Heart 2002; 87: 346-349.
4. Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003; 60: 1676-1679.
5. Buyse G, Mertens L, Di Salvo G, et al. Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring. Neurology 2003; 60: 1679-1681.
6. Muhlenhoff U, Richhardt N, Ristow M, Kispal G, Lill R. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum Mol Genet 2002; 11: 2025-2036.
7. Tan G, Napoli E, Taroni F, Cortopassi G. Decreased expression of genes involved in sulfur amino acid metabolism in frataxin-deficient cells. Hum Mol Genet 2003; 12: 1-13.
8. Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann Neurol 2001; 49: 590-596.